XGN: Exagen, Inc.
About
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
Current Value
$3.791 Year Return
Current Value
$3.791 Year Return
Key Details
Market Cap
$62.26M
P/E Ratio
-3.76
1Y Stock Return
127.74%
1Y Revenue Growth
8.00%
Dividend Yield
0.00%
Price to Book
4.8
Strategies that include XGN
Stock's related to XGN
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QNTM | 28.81% | $9.19M | -94.36% | 0.00% |
| DOCS | 26.33% | $9.62B | +114.35% | 0.00% |
| NTRA | 26.30% | $21.40B | +200.46% | 0.00% |
| ADMA | 24.68% | $4.88B | +423.60% | 0.00% |
| ESTA | 24.09% | $968.33M | +54.98% | 0.00% |
| ABUS | 23.71% | $661.33M | +90.71% | 0.00% |
| PNTG | 23.52% | $1.09B | +133.90% | 0.00% |
| TTD | 23.23% | $58.94B | +81.35% | 0.00% |
| KODK | 22.96% | $422.90M | +41.40% | 0.00% |
| PX | 22.55% | $1.38B | +31.13% | 1.10% |
| NECB | 22.00% | $415.57M | +76.37% | 1.37% |
| ACIC | 21.91% | $631.49M | +58.21% | 0.00% |
| GRAL | 21.56% | $459.22M | -13.00% | 0.00% |
| BBDO | 21.26% | $11.37B | -14.00% | 1.66% |
| ICUI | 20.92% | $4.15B | +104.38% | 0.00% |
| CHRS | 20.78% | $94.65M | -58.72% | 0.00% |
| BCH | 20.65% | $11.70B | +6.43% | 0.00% |
| MEG | 20.57% | $564.59M | -47.13% | 0.00% |
| DHC | 20.46% | $593.54M | +22.39% | 1.65% |
| WAL | 20.10% | $9.81B | +84.63% | 1.67% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LEGN | 0.01% | $7.04B | -32.93% | 0.00% |
| PTEN | -0.01% | $3.16B | -31.96% | 3.93% |
| NXE | -0.02% | $4.79B | +29.91% | 0.00% |
| ASND | -0.02% | $7.44B | +33.23% | 0.00% |
| IMXI | 0.02% | $651.21M | -1.55% | 0.00% |
| NVO | 0.03% | $342.62B | -0.15% | 1.40% |
| INTC | -0.03% | $104.37B | -44.55% | 1.55% |
| ORN | 0.03% | $333.77M | +78.01% | 0.00% |
| INSW | 0.03% | $2.07B | +1.70% | 1.14% |
| RIG | -0.04% | $3.68B | -33.12% | 0.00% |
| SEI | 0.04% | $616.12M | +133.06% | 2.39% |
| TIGR | 0.04% | $869.81M | +19.38% | 0.00% |
| ALSN | 0.05% | $10.05B | +115.86% | 0.86% |
| BJRI | -0.06% | $780.10M | +11.11% | 0.00% |
| CNDT | 0.06% | $569.21M | +20.27% | 0.00% |
| NFE | -0.06% | $2.29B | -74.75% | 3.32% |
| CTVA | -0.06% | $40.03B | +25.87% | 1.11% |
| PAYC | 0.06% | $12.12B | +21.78% | 0.69% |
| CR | 0.07% | $10.21B | +67.24% | 0.45% |
| LE | 0.07% | $461.65M | +114.49% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVD | -22.18% | $182.80M | -32.45% | 1.42% |
| MCK | -20.40% | $78.15B | +35.51% | 0.42% |
| IRWD | -19.13% | $609.71M | -59.34% | 0.00% |
| DAVA | -18.66% | $1.16B | -59.28% | 0.00% |
| PCRX | -17.33% | $772.48M | -37.25% | 0.00% |
| ATNM | -15.79% | $44.30M | -67.05% | 0.00% |
| DLB | -14.88% | $6.76B | -16.58% | 1.69% |
| ARWR | -14.61% | $2.31B | -34.44% | 0.00% |
| MOV | -14.37% | $419.99M | -35.54% | 7.49% |
| GSBD | -14.01% | $1.53B | - | 13.99% |
| PTMN | -13.55% | - | - | 16.06% |
| INCY | -12.76% | $13.59B | +32.56% | 0.00% |
| MMC | -12.68% | $108.41B | +10.89% | 1.37% |
| PGR | -12.42% | $149.10B | +57.29% | 0.45% |
| ELVN | -12.31% | $1.28B | +135.01% | 0.00% |
| CAH | -11.75% | $28.64B | +12.14% | 1.70% |
| ZBH | -11.72% | $22.09B | -1.73% | 0.87% |
| NTIC | -11.07% | $132.27M | +24.98% | 2.02% |
| FIGS | -11.06% | $840.56M | -25.56% | 0.00% |
| SW | -11.01% | $13.78B | +15.02% | 1.14% |
ETF's related to XGN
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FBY | -0.02% | $127.69M | 0.99% |
| FLMI | 0.16% | $356.19M | 0.3% |
| FTGC | -0.18% | $2.17B | 1.02% |
| CRPT | -0.20% | $94.50M | 0.85% |
| VIXY | -0.24% | $195.31M | 0.85% |
| PREF | 0.25% | $999.92M | 0.55% |
| CORN | -0.29% | $61.12M | 0.2% |
| PULS | -0.31% | $8.78B | 0.15% |
| PGHY | 0.33% | $141.95M | 0.35% |
| IAK | -0.38% | $760.79M | 0.39% |
| BSCO | -0.40% | $2.35B | 0.1% |
| SMB | -0.44% | $266.77M | 0.07% |
| UNG | -0.52% | $908.80M | 1.06% |
| VPC | 0.60% | $52.32M | 9.72% |
| XYLD | 0.62% | $2.89B | 0.6% |
| BIZD | 0.66% | $1.25B | 13.33% |
| JPST | -0.68% | $28.43B | 0.18% |
| PBP | 0.71% | $92.98M | 0.2% |
| CDC | 0.76% | $821.08M | 0.38% |
| CANE | -0.79% | $17.72M | 0.29% |
News
Yahoo
Exagen ( NASDAQ:XGN ) Third Quarter 2024 Results Key Financial Results Revenue: US$12.5m (down 6.8% from 3Q 2023). Net...
Yahoo
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune diseaseCARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis (RA) biomarkers, to be incorporated into the AVISE CTD platform. Collectively, these new biomarkers will further improve th
Yahoo
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Company presentation by John Aballi, President and CEO on Thursday, November 21, 2024, at 3:00 p.m. EST at the Westin NY Grand Central Hotel. Management will also participate in one-on-one investor
Yahoo
Exagen Inc (XGN) reports improved financial metrics despite one-time adjustments, with promising prospects from new biomarker launches.
Yahoo
Q3 2024 Exagen Inc Earnings Call
Yahoo
Exagen (XGN) delivered earnings and revenue surprises of 6.67% and 7.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.